Evidence Summary
- Evidence Level
- Moderate
- Mechanism
- Antiviral / Persistence, Enrollment: Actual, Enrollment: Estimated, Sponsor Type: Network
- Safety
- Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.
- Dosing
- See linked studies/trials for reported doses and durations; typical protocols vary widely.
Investigational for listed conditions. 5 associated trial(s) and 3 study reference(s) in current data. Review primary sources and consult specialists before use.
Clinical Trials
5 trial(s) registered
| NCT ID | Title | Phase | Status |
|---|---|---|---|
| NCT07597902 | SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction | Phase 2 | Not yet recruiting |
| NCT05965726 | RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms | Phase 2 | Completed |
| NCT05595369 | RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms | Phase 2 | Completed |
| NCT05852873 | PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway | Phase 3 | Active, not recruiting |
| NCT05576662 | Paxlovid for Treatment of Long Covid | Phase 2 | Completed |